FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017306987> ?p ?o ?g. }

• W3017306987 endingPage "935" @default.
• W3017306987 startingPage "922" @default.
• W3017306987 abstract "Improper activity of bone-resorbing osteoclasts results in low bone density and deterioration of bone structure, which increase the risk of fractures. Anti-resorptive therapies targeting osteoclasts have proven effective in preserving bone mass, but these therapeutic agents lead to defective new bone formation and numerous potential side effects. In this study, we demonstrate that recombinant adeno-associated virus, serotype 9 (rAAV9) can deliver to osteoclasts an artificial microRNA (amiR) that silences expression of key osteoclast regulators, RANK (receptor activator for nuclear factor κB) and cathepsin K (rAAV9.amiR-rank, rAAV9.amiR-ctsk), to prevent bone loss in osteoporosis. As rAAV9 is highly effective for the transduction of osteoclasts, systemic administration of rAAV9 carrying amiR-rank or amiR-ctsk results in a significant increase of bone mass in mice. Furthermore, the bone-targeting peptide motif (Asp)14 or (AspSerSer)6 was grafted onto the AAV9-VP2 capsid protein, resulting in significant reduction of transgene expression in non-bone peripheral organs. Finally, systemic delivery of bone-targeting rAAV9.amiR-ctsk counteracts bone loss and improves bone mechanical properties in mouse models of postmenopausal and senile osteoporosis. Collectively, inhibition of osteoclast-mediated bone resorption via bone-targeting rAAV9-mediated silencing of ctsk is a promising gene therapy that can preserve bone formation and mitigate osteoporosis, while limiting adverse off-target effects. Improper activity of bone-resorbing osteoclasts results in low bone density and deterioration of bone structure, which increase the risk of fractures. Anti-resorptive therapies targeting osteoclasts have proven effective in preserving bone mass, but these therapeutic agents lead to defective new bone formation and numerous potential side effects. In this study, we demonstrate that recombinant adeno-associated virus, serotype 9 (rAAV9) can deliver to osteoclasts an artificial microRNA (amiR) that silences expression of key osteoclast regulators, RANK (receptor activator for nuclear factor κB) and cathepsin K (rAAV9.amiR-rank, rAAV9.amiR-ctsk), to prevent bone loss in osteoporosis. As rAAV9 is highly effective for the transduction of osteoclasts, systemic administration of rAAV9 carrying amiR-rank or amiR-ctsk results in a significant increase of bone mass in mice. Furthermore, the bone-targeting peptide motif (Asp)14 or (AspSerSer)6 was grafted onto the AAV9-VP2 capsid protein, resulting in significant reduction of transgene expression in non-bone peripheral organs. Finally, systemic delivery of bone-targeting rAAV9.amiR-ctsk counteracts bone loss and improves bone mechanical properties in mouse models of postmenopausal and senile osteoporosis. Collectively, inhibition of osteoclast-mediated bone resorption via bone-targeting rAAV9-mediated silencing of ctsk is a promising gene therapy that can preserve bone formation and mitigate osteoporosis, while limiting adverse off-target effects." @default.
• W3017306987 created "2020-04-24" @default.
• W3017306987 creator A5000341131 @default.
• W3017306987 creator A5009470292 @default.
• W3017306987 creator A5016044196 @default.
• W3017306987 creator A5023010534 @default.
• W3017306987 creator A5024038808 @default.
• W3017306987 creator A5031006237 @default.
• W3017306987 creator A5052209069 @default.
• W3017306987 creator A5058380236 @default.
• W3017306987 creator A5077553920 @default.
• W3017306987 creator A5083613726 @default.
• W3017306987 creator A5088115504 @default.
• W3017306987 date "2020-06-01" @default.
• W3017306987 modified "2023-10-17" @default.
• W3017306987 title "Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy" @default.
• W3017306987 cites W1500392367 @default.
• W3017306987 cites W1534645474 @default.
• W3017306987 cites W1544405851 @default.
• W3017306987 cites W1840644602 @default.
• W3017306987 cites W1979678145 @default.
• W3017306987 cites W1981577989 @default.
• W3017306987 cites W1984965767 @default.
• W3017306987 cites W1995808441 @default.
• W3017306987 cites W2000647744 @default.
• W3017306987 cites W2000695783 @default.
• W3017306987 cites W2003508313 @default.
• W3017306987 cites W2004590552 @default.
• W3017306987 cites W2008756438 @default.
• W3017306987 cites W2010654750 @default.
• W3017306987 cites W2013908114 @default.
• W3017306987 cites W2025062557 @default.
• W3017306987 cites W2025162592 @default.
• W3017306987 cites W2026130929 @default.
• W3017306987 cites W2028917977 @default.
• W3017306987 cites W2035337493 @default.
• W3017306987 cites W2036368043 @default.
• W3017306987 cites W2043007466 @default.
• W3017306987 cites W2047103966 @default.
• W3017306987 cites W2048346627 @default.
• W3017306987 cites W2053755635 @default.
• W3017306987 cites W2059659235 @default.
• W3017306987 cites W2081064825 @default.
• W3017306987 cites W2084103516 @default.
• W3017306987 cites W2087378917 @default.
• W3017306987 cites W2105456308 @default.
• W3017306987 cites W2107813922 @default.
• W3017306987 cites W2109349667 @default.
• W3017306987 cites W2114929846 @default.
• W3017306987 cites W2117025246 @default.
• W3017306987 cites W2120193263 @default.
• W3017306987 cites W2122467899 @default.
• W3017306987 cites W2131862834 @default.
• W3017306987 cites W2142695353 @default.
• W3017306987 cites W2166739815 @default.
• W3017306987 cites W2524977260 @default.
• W3017306987 cites W2606189634 @default.
• W3017306987 cites W2617839298 @default.
• W3017306987 cites W2765466781 @default.
• W3017306987 cites W2913212173 @default.
• W3017306987 cites W2923685508 @default.
• W3017306987 cites W2954037482 @default.
• W3017306987 cites W2990783641 @default.
• W3017306987 doi "https://doi.org/10.1016/j.omtm.2020.04.010" @default.
• W3017306987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7210389" @default.
• W3017306987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32405514" @default.
• W3017306987 hasPublicationYear "2020" @default.
• W3017306987 type Work @default.
• W3017306987 sameAs 3017306987 @default.
• W3017306987 citedByCount "28" @default.
• W3017306987 countsByYear W30173069872020 @default.
• W3017306987 countsByYear W30173069872021 @default.
• W3017306987 countsByYear W30173069872022 @default.
• W3017306987 countsByYear W30173069872023 @default.
• W3017306987 crossrefType "journal-article" @default.
• W3017306987 hasAuthorship W3017306987A5000341131 @default.
• W3017306987 hasAuthorship W3017306987A5009470292 @default.
• W3017306987 hasAuthorship W3017306987A5016044196 @default.
• W3017306987 hasAuthorship W3017306987A5023010534 @default.
• W3017306987 hasAuthorship W3017306987A5024038808 @default.
• W3017306987 hasAuthorship W3017306987A5031006237 @default.
• W3017306987 hasAuthorship W3017306987A5052209069 @default.
• W3017306987 hasAuthorship W3017306987A5058380236 @default.
• W3017306987 hasAuthorship W3017306987A5077553920 @default.
• W3017306987 hasAuthorship W3017306987A5083613726 @default.
• W3017306987 hasAuthorship W3017306987A5088115504 @default.
• W3017306987 hasBestOaLocation W30173069871 @default.
• W3017306987 hasConcept C101990758 @default.
• W3017306987 hasConcept C104317684 @default.
• W3017306987 hasConcept C119056186 @default.
• W3017306987 hasConcept C126322002 @default.
• W3017306987 hasConcept C134018914 @default.
• W3017306987 hasConcept C141071460 @default.
• W3017306987 hasConcept C170033053 @default.
• W3017306987 hasConcept C170493617 @default.
• W3017306987 hasConcept C185592680 @default.
• W3017306987 hasConcept C2776033226 @default.
• W3017306987 hasConcept C2776541429 @default.

• next